Back to Journals » Breast Cancer: Targets and Therapy » Volume 12

A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma

Authors Kunnuru SKR, Thiyagarajan M, Martin Daniel J, Singh K B

Received 28 August 2020

Accepted for publication 21 October 2020

Published 20 November 2020 Volume 2020:12 Pages 259—266

DOI https://doi.org/10.2147/BCTT.S277588

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Pranela Rameshwar


Supreeth Kumar Reddy Kunnuru,1 Manuneethimaran Thiyagarajan,1 Jovita Martin Daniel,2 Balaji Singh K1

1General Surgery Department, Sri Ramachandra Medical University, Chennai 600116, India; 2Medical Oncology Department, Sri Ramachandra Medical University, Chennai 600116, India

Correspondence: Manuneethimaran Thiyagarajan
General Surgery Department, Sri Ramachandra Medical University, 9036, Tower 9b, Prestige, Iyyapanthanagal, Chennai 614613, India
Tel +91 9952044955
Email profmaran@gmail.com
Jovita Martin Daniel Medical Oncology Department
Sri Ramachandra Medical University, Porur, Chennai 600116, India
Porur Email jovimartin4@gmail.com

Aim and objectives: To assess the effectiveness of neo-adjuvant chemotherapy and its impact on the clinical and pathological response in locally advanced breast cancer. To compare molecular subtypes of breast cancer with response to neo-adjuvant chemotherapy.
Patients and methods: This was a prospective study on patients who received neoadjuvant chemotherapy for breast carcinoma for a 3-year period. A total of 60 patients who presented with locally advanced breast cancer (LABC) were treated with neoadjuvant chemotherapy. Forty patients were treated with the 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) schedule, 16 patients were treated with Adriamycin and cyclophosphamide (AC), and four patients were treated with oral cyclophosphamide, intravenous methotrexate, and fluorouracil (CMF). Taxol was added in all node-positive cases, triple negative breast cancer (TNBC), and Her 2 positive cases. The clinical response was assessed with RECIST criteria after neoadjuvant chemotherapy. The response was compared with molecular subtypes of carcinoma breast and receptor status individually.
Results: A total of 60 female patients receiving primary chemotherapy for locally advanced breast malignancy were studied. The median age of the patients at the time of diagnosis was 44 years (range=24– 73). In terms of menopausal status, 25 (42%) patients were pre-menopausal and 35 (58%) patients were post-menopausal. Histological classification showed invasive ductal carcinoma in 72% of patients, invasive lobular carcinoma in 15% of patients, and other types including mixed patterns in 13% of patients. Among 60 patients, 16 patients (26.6%) had clinically complete remission (cCR), 30 patients (50%) had partial remission, eight patients (13.3%) had stable disease, and six patients (10%) had progressive disease. Following neoadjuvant chemotherapy, 46 (76.6%) patient underwent Modified radical mastectomy surgery. Target therapy was given for Her2 neu patients after surgery. Hormonal therapy was added to hormone ER PR positive cases postoperatively. Eight patients (13.3%) among this operated cases attained complete pathological response.
Conclusion: Preoperative chemotherapy downstages the primary tumors and axillary metastasis in patients with locally advanced breast carcinoma. Comparison of molecular subtypes with chemotherapy response is a better way to find out the predictors of response to chemotherapy.

Keywords: neoadjuvant chemotherapy, carcinoma breast, predictors of NACT response, clinical and pathological response to NACT

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]